MARKET

GLMD

GLMD

Galmed Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.370
-0.070
-1.58%
Closed 16:06 11/15 EST
OPEN
4.380
PREV CLOSE
4.440
HIGH
4.510
LOW
4.300
VOLUME
29.90K
TURNOVER
--
52 WEEK HIGH
9.74
52 WEEK LOW
3.418
MARKET CAP
92.31M
P/E (TTM)
-5.8050
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of GLMD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

GLMD News

  • Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.11/10 13:50
  • Edited Transcript of GLMD earnings conference call or presentation 6-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/09 03:57
  • The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings
  • Benzinga.11/06 13:21
  • Galmed Pharmaceuticals Q3 EPS $(0.21) Beats $(0.29) Estimate
  • Benzinga.11/06 12:18

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About GLMD

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate, aramchol, is a disease modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). The Company's Aramchol is a conjugate of cholic acid and arachidic acid, which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.
More

Webull offers Galmed Pharmaceuticals Ltd (GLMD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.